ArticleArthritis care & research2016
Risk of Pulmonary Embolism and Deep Venous Thrombosis in Systemic Sclerosis: A General Population-Based Study.
Article in Arthritis care & research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 3 syntheses or guidelines pooled it, 56 citations in OpenAlex.
- Association between systemic sclerosis and risk of cerebrovascular and cardiovascular disease: a meta-analysis.Scientific reports · 2024Pooled it
- Prevalence and Clinical Associations of Antiphospholipid Antibodies in Systemic Sclerosis: New Data From a French Cross-Sectional Study, Systematic Review, and Meta-Analysis.Frontiers in immunology · 2018Pooled it
- Idiopathic inflammatory myopathy and the risk of venous thromboembolism: a meta-analysis.Rheumatology international · 2017Pooled it
- Venous thromboembolism and bleeding in cancer patients: role of inflammatory and cardiac biomarkers.European heart journal · 2026Trial
- The Plasma Levels of ADAMTS-13, von Willebrand Factor, VWFpp, and Fibrin-Related Markers in Patients With Systemic Sclerosis Having Thrombosis.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis · 2018Trial
- Varicose veins and venous thromboembolism in inflammatory rheumatic diseases: vascular complications and rehabilitation approaches.Rheumatology international · 2026Review
- Under the dual effect of inflammation and pulmonary fibrosis, CTD-ILD patients possess a greater susceptibility to VTE.Thrombosis journal · 2024Review
- A journey to vasculopathy in systemic sclerosis: focus on haemostasis and thrombosis.Clinical and experimental medicine · 2023Review
- Systemic sclerosis. Part II: perioperative considerations.BJA education · 2023Review
- Acute limb ischemia in an adolescent with COVID-19 and systemic scleroderma: a case report.BMC pediatrics · 2022Article
- Clinical characteristics and outcomes in pulmonary manifestations of systemic sclerosis: Contribution from pulmonary hypertension and interstitial lung disease severity.Pulmonary circulation · 2022Article
- Systemic sclerosis complicated by chronic thromboembolic pulmonary hypertension treated with balloon pulmonary angioplasty: a case report.European heart journal. Case reports · 2022Article
- The clinical significance of a shortened activated partial thromboplastin time in patients with connective tissue disease.Clinical rheumatology · 2021Article
- Pulmonary hypertension phenotypes in patients with systemic sclerosis.European respiratory review : an official journal of the European Respiratory Society · 2021Review
- High D-dimer plasma concentration in systemic sclerosis patients: Prevalence and association with vascular complications.Journal of scleroderma and related disorders · 2021Article
- [Clinical and immunological characteristics of myositis complicated with thromboembolism].Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences · 2020Article
- An Update on Systemic Sclerosis and its Perioperative Management.Current anesthesiology reports · 2020Review
- Management of Pulmonary Arterial Hypertension in Patients with Systemic Sclerosis.Integrated blood pressure control · 2020Review
- Management of Chronic Respiratory Failure in Interstitial Lung Diseases: Overview and Clinical Insights.International journal of medical sciences · 2019Review
- The role of pulmonary arterial hypertension-targeted therapy in systemic sclerosis.F1000Research · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
Abstract
objectiveTo determine the risk of venous thromboembolism (VTE) (pulmonary embolism [PE] and deep vein thrombosis [DVT]) in individuals with incident systemic sclerosis (SSc; scleroderma) in the general population.
methodsUsing a population database that includes all residents of British Columbia, Canada, we conducted a cohort study of all patients with incident SSc and up to 10 age-, sex-, and entry time-matched individuals from the general population. We compared incidence rates of PE, DVT, and VTE between the 2 groups according to SSc disease duration. We calculated hazard ratios (HRs), adjusting for confounders.
resultsAmong 1,245 individuals with SSc (83% female, mean age 56 years), the incidence rates of PE, DVT, and VTE were 3.47, 3.48, and 6.56 per 1,000 person-years, respectively, whereas the corresponding rates were 0.78, 0.76, and 1.37 per 1,000 person-years among 12,670 non-SSc individuals. Compared with non-SSc individuals, the multivariable HRs among SSc patients were 3.73 (95% confidence interval [95% CI] 1.98-7.04), 2.96 (95% CI 1.54-5.69), and 3.47 (95% CI 2.14-5.64) for PE, DVT, and VTE, respectively. The age-, sex-, and entry time-matched HRs for PE, DVT, and VTE were highest during the first year after SSc diagnosis (32.77 [95% CI 6.60-162.75], 8.50 [95% CI 3.13-23.04], and 12.03 [95% CI 5.27-27.45], respectively).
conclusionThese findings provide population-based evidence that SSc patients are at a substantially increased risk of VTE, especially within the first year after SSc diagnosis. Increased monitoring for this potentially fatal outcome and its modifiable risk factors is warranted in this patient population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.